Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure (EarlyDry)
Acute Kidney Injury, Fluid Overload
About this trial
This is an interventional other trial for Acute Kidney Injury focused on measuring Renal Replacement Therapy (RRT), Ultrafiltration, Deresuscitation, Fluid balance, Fluid overload, Tissue perfusion
Eligibility Criteria
Inclusion Criteria: Acute kidney injury treated by continuous renal replacement therapy in ICU less than 7 days, At least 1 organ failure during ICU in addition to AKI (mechanical ventilation or vasopressors administration>12 hours), Cumulative UF net less than 1000ml before inclusion, Norepinephrine < 0,5 µg/kg/min, Absence of hypoperfusion signs, Fluid overload defined as follows : fluid overload > 5% of base weight (based on cumulative fluid balance or a weight gain) and/or peripheral edema (AKIKI edema scale > 2). Exclusion Criteria: Chronic renal failure hemodialyzed before admission to the ICU, Mechanical circulatory support (ECMO, LVAD), Pregnant, child -bearing age or lactating women, Stroke less than 30 days, Intestinal ischemia less than 7 days documented non-operated, Interventional study participation or exclusion period on going, Guardianship, curatorship or safeguard of justice, Absence of signature of free and informed consent by the patient and/or relative, Patients not affiliated to a social security scheme or beneficiaries of a similar scheme
Sites / Locations
- Service d'Anesthesie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon
- Service de Réanimation, CHU de Dijon
- Service de Réanimation, Hôpital Michallon
- Service Anesthésie Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon
- Service de Réanimation, Clinique de la Sauvegarde
- Département d'anesthésie réanimation Hôpital Européen Georges Pompidou
- Service de Réanimation, Centre Hospitalier Universitaire de Saint-Étienne
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Corrective strategy
Stabilizing strategy
In the experimental group, all patients will have a UFnet settled (2 ml/kg/h ) in order to reach the patient baseline body weight.
In the control group, all patients will have a UFnet 2 ml settled (0 to 1 ml/kg/h) in order to stabilize the patient body weight.